A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Public ClinicalTrials.gov record NCT06818812. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label, Multicenter Study of INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Study identification
- NCT ID
- NCT06818812
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Incyte Corporation
- Industry
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Interventions
- Cetuximab Drug
- GEMNabP Drug
- INCB186748 Drug
- mFOLFIRINOX Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 26, 2025
- Primary completion
- Mar 26, 2027
- Completion
- Mar 26, 2027
- Last update posted
- Mar 22, 2026
2025 – 2027
United States locations
- U.S. sites
- 9
- U.S. states
- 9
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Healthcare Hematology-Oncology | Santa Monica | California | 90404 | — |
| Sarah Cannon Research Institue At Healthone | Denver | Colorado | 80218 | — |
| Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | — |
| Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins | Baltimore | Maryland | 21287-7049 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Jefferson University Hospitals | Philadelphia | Pennsylvania | 19107 | — |
| Scri Oncology Partners | Nashville | Tennessee | 37203 | — |
| Md Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06818812, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 22, 2026 · Synced Apr 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06818812 live on ClinicalTrials.gov.